From the public announcements of discontinued research, the fuzzy CBO math that is under-counting the reductions in cures, to the bloated use of taxpayer dollars to implement price control. Its a data rich discussion that's sure to send shivers down the spines of policymakers, practitioners , and patients alike.

Tom can be found: https://www.linkedin.com/in/tomas-j-philipson-02878024/